

Lupin receives approval for Leflunomide Tablets

05 February 2020 | News | By Kalyani Sharma

The product would be manufactured at Lupin's Pithampur (Unit 1) facility, India



Lupin Limited has announced the approval for its Leflunomide Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration, to market a generic equivalent of Arava® Tablets, 10 mg and 20 mg, of Sanofi Aventis.

The product would be manufactured at Lupin's Pithampur (Unit 1) facility, India.

Leflunomide Tablets USP, 10 mg and 20 mg, are indicated for the treatment of adults with active rheumatoid arthritis (RA).

Leflunomide Tablets USP (RLD: Arava® Tablets) had an annual sales of approximately USD 44 million in the U.S. (IQVIA MAT December 2019).